| General Information of Drug Metabolite (DM) (ID: DM018000) |
| DM Name |
GDC-0623 M14
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Unclear - Unclear |
GDC-0623
|
[1] |
|
Mephenytoin 4-hydroxylase (CYP2C19)
|
DME0021
|
| Unclear - Unclear |
GDC-0623
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| GDC-0623 |
DR4047
|
Phase 1 |
Solid tumour/cancer |
|
|
| References |
| 1 |
Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
